Tenascin-C in cardiovascular tissue remodeling - From development to inflammation and repair -

Circulation Journal

Volumn 76, Issue 11, 2012, Pages 2513-2520

  Imanaka Yoshida, Kyoko ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

Biomarker; Inflammation; Molecular imaging; Remodeling; Tenascin C

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BRAIN NATRIURETIC PEPTIDE; MATRIX METALLOPROTEINASE; SCLEROPROTEIN; TENASCIN;

ANGIOGENESIS; CELL ADHESION; CONGESTIVE CARDIOMYOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; HEART DEVELOPMENT; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; MYOFIBROBLAST; PROTEIN EXPRESSION; REVIEW; TISSUE REPAIR;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CELL ADHESION; COLLAGENASES; EMBRYONIC DEVELOPMENT; HUMANS; MYOCYTES, CARDIAC; MYOFIBROBLASTS; NEOVASCULARIZATION, PHYSIOLOGIC; TENASCIN; UP-REGULATION;

EID: 84869129525     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1033     Document Type: Review

References (97)

1. Bornstein P. Diversity of function is inherent in matricellular proteins: An appraisal of thrombospondin 1. J Cell Biol 1995; 130: 503-506.
2. Bornstein P, Sage EH. Matricellular proteins: Extracellular modulators of cell function. Curr Opin Cell Biol 2002; 14: 608-616.
3. Schellings MW, Pinto YM, Heymans S. Matricellular proteins in the heart: Possible role during stress and remodeling. Cardiovasc Res 2004; 64: 24-31.
4. Matsui Y, Morimoto J, Uede T. Role of matricellular proteins in cardiac tissue remodeling after myocardial infarction. World J Biol Chem 2010; 1: 69-80.
5. Frangogiannis NG. Matricellular proteins in cardiac adaptation and disease. Physiol Rev 2012; 92: 635-688.
6. Okamoto H, Imanaka-Yoshida K. Matricellular proteins: New molecular targets to prevent heart failure. Cardiovasc Ther 2012; 30: e198-e209.
7. Tucker RP, Chiquet-Ehrismann R. The regulation of tenascin expression by tissue microenvironments. Biochim Biophys Acta 2009; 1793: 888-892.
8. Midwood KS, Hussenet T, Langlois B, Orend G. Advances in tenas-cin-C biology. Cell Mol Life Sci 2011; 68: 3175-3199.
9. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett 2006; 244: 143-163.
10. Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal 2009; 3: 287-310.
11. Chiquet-Ehrismann R, Chiquet M. Tenascins: Regulation and putative functions during pathological stress. J Pathol 2003; 200: 488-499.
12. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: Structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000; 218: 235-259.
13. Udalova IA, Ruhmann M, Thomson SJ, Midwood KS. Expression and immune function of tenascin-C. Crit Rev Immunol 2011; 31: 115-145.
14. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451: 147-152.
15. Chen C, Wu CQ, Zhang ZQ, Yao DK, Zhu L. Loss of expression of miR-335 is implicated in hepatic stellate cell migration and activation. Exp Cell Res 2011; 317: 1714-1725.
16. Saga Y, Yagi T, Ikawa Y, Sakakura T, Aizawa S. Mice develop normally without tenascin. Genes Dev 1992; 6: 1821-1831.
17. Forsberg E, Hirsch E, Frohlich L, Meyer M, Ekblom P, Aszodi A, et al. Skin wounds and severed nerves heal normally in mice lacking tenascin-C. Proc Natl Acad Sci USA 1996; 93: 6594-6599.
18. Roth-Kleiner M, Hirsch E, Schittny JC. Fetal lungs of tenascin-Cdeficient mice grow well, but branch poorly in organ culture. Am J Respir Cell Mol Biol 2004; 30: 360-366.
19. Ishii K, Imanaka-Yoshida K, Yoshida T, Sugimura Y. Role of stromal tenascin-C in mouse prostatic development and epithelial cell differentiation. Dev Biol 2008; 324: 310-319.
20. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, Nishioka T, Inada H, Hiroe M, et al. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol 2005; 167: 71-80.
21. Sawada Y, Onoda K, Imanaka-Yoshida K, Maruyama J, Yamamoto K, Yoshida T, et al. Tenascin-C synthesized in both donor grafts and recipients accelerates artery graft stenosis. Cardiovasc Res 2007; 74: 366-376.
22. Yamamoto K, Onoda K, Sawada Y, Fujinaga K, Imanaka-Yoshida K, Shimpo H, et al. Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice. Cardiovasc Res 2005; 65: 737-742.
23. Nakahara H, Gabazza EC, Fujimoto H, Nishii Y, D'Alessandro-Gabazza CN, Bruno NE, et al. Deficiency of tenascin C attenuates allergen-induced bronchial asthma in the mouse. Eur J Immunol 2006; 36: 3334-3345.
24. El-Karef A, Yoshida T, Gabazza EC, Nishioka T, Inada H, Sakakura T, et al. Deficiency of tenascin-C attenuates liver fibrosis in immunemediated chronic hepatitis in mice. J Pathol 2007; 211: 86-94.
25. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, et al. Tenascin-C is an endogenous activator of toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009; 15: 774-780.
26. Nishioka T, Onishi K, Shimojo N, Nagano Y, Matsusaka H, Ikeuchi M, et al. Tenascin-C may aggravate left ventricular remodeling and function after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2010; 298: H1072-H1078.
27. Imanaka-Yoshida K, Matsumoto K, Hara M, Sakakura T, Yoshida T. The dynamic expression of tenascin-C and tenascin-X during early heart development in the mouse. Differentiation 2003; 71: 291-298.
28. Snarr BS, Kern CB, Wessels A. Origin and fate of cardiac mesenchyme. Dev Dyn 2008; 237: 2804-2819.
29. Perez-Pomares JM, de la Pompa JL. Signaling during epicardium and coronary vessel development. Circ Res 2011; 109: 1429-1442.
30. Ando K, Takahashi M, Yamagishi T, Miyagawa-Tomita S, Imanaka-Yoshida K, Yoshida T, et al. Tenascin C may regulate the recruitment of smooth muscle cells during coronary artery development. Differentiation 2011; 81: 299-306.
31. Ishigaki T, Imanaka-Yoshida K, Shimojo N, Matsushima S, Taki W, Yoshida T. Tenascin-C enhances crosstalk signaling of integrin alphavbeta3/ PDGFR-beta complex by SRC recruitment promoting PDGF-induced proliferation and migration in smooth muscle cells. J Cell Physiol 2011; 226: 2617-2624.
32. Willems IE, Arends JW, Daemen MJ. Tenascin and fibronectin expression in healing human myocardial scars. J Pathol 1996; 179: 321-325.
33. Imanaka-Yoshida K, Hiroe M, Nishikawa T, Ishiyama S, Shimojo T, Ohta Y, et al. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest 2001; 81: 1015-1024.
34. Sato A, Aonuma K, Imanaka-Yoshida K, Yoshida T, Isobe M, Kawase D, et al. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol 2006; 47: 2319-2325.
35. Odaka K, Uehara T, Arano Y, Adachi S, Tadokoro H, Yoshida K, et al. Noninvasive detection of cardiac repair after acute myocardial infarction in rats by 111 In Fab fragment of monoclonal antibody specific for tenascin-C. Int Heart J 2008; 49: 481-492.
36. Imanaka-Yoshida K, Hiroe M, Yasutomi Y, Toyozaki T, Tsuchiya T, Noda N, et al. Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol 2002; 197: 388-394.
37. Sato M, Toyozaki T, Odaka K, Uehara T, Arano Y, Hasegawa H, et al. Detection of experimental autoimmune myocarditis in rats by 111In monoclonal antibody specific for tenascin-C. Circulation 2002; 106: 1397-1402.
38. Morimoto S, Imanaka-Yoshida K, Hiramitsu S, Kato S, Ohtsuki M, Uemura A, et al. Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. J Pathol 2005; 205: 460-467.
39. Frangogiannis NG, Shimoni S, Chang SM, Ren G, Dewald O, Gersch C, et al. Active interstitial remodeling: An important process in the hibernating human myocardium. J Am Coll Cardiol 2002; 39: 1468-1474.
40. Taki J, Inaki A, Wakabayashi H, Imanaka-Yoshida K, Ogawa K, Hiroe M, et al. Dynamic expression of tenascin-C after myocardial ischemia and reperfusion: Assessment by 125I-anti-tenascin-C antibody imaging. J Nucl Med 2010; 51: 1116-1122.
41. Nishioka T, Suzuki M, Onishi K, Takakura N, Inada H, Yoshida T, et al. Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: Involvement of tenascin-C induced by aldosterone-mediated inflammation. J Cardiovasc Pharmacol 2007; 49: 261-268.
42. Franz M, Grun K, Richter P, Brehm BR, Fritzenwanger M, Hekmat K, et al. Extra cellular matrix remodelling after heterotopic rat heart transplantation: Gene expression profiling and involvement of ED-A+ fibronectin, alpha-smooth muscle actin and B+ tenascin-C in chronic cardiac allograft rejection. Histochem Cell Biol 2010; 134: 503-517.
43. Tamura A, Kusachi S, Nogami K, Yamanishi A, Kajikawa Y, Hirohata S, et al. Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy: Distribution along margin of fibrotic lesions. Heart 1996; 75: 291-294.
44. Tsukada B, Terasaki F, Shimomura H, Otsuka K, Katashima T, Fujita S, et al. High prevalence of chronic myocarditis in dilated cardiomyopathy referred for left ventriculoplasty: Expression of tenascin C as a possible marker for inflammation. Hum Pathol 2009; 40: 1015-1022.
45. Goh FG, Piccinini AM, Krausgruber T, Udalova IA, Midwood KS. Transcriptional regulation of the endogenous danger signal tenascin-C: A novel autocrine loop in inflammation. J Immunol 2010; 184: 2655-2662.
46. Kanayama M, Morimoto J, Matsui Y, Ikesue M, Danzaki K, Kurotaki D, et al. Alpha9beta1 integrin-mediated signaling serves as an intrinsic regulator of pathogenic Th17 cell generation. J Immunol 2011; 187: 5851-5864.
47. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008; 58: 88-111.
48. Dobaczewski M, Gonzalez-Quesada C, Frangogiannis NG. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol 2010; 48: 504-511.
49. Imanaka-Yoshida K, Hiroe M, Yoshida T. Interaction between cell and extracellular matrix in heart disease: Multiple roles of tenascin-C in tissue remodeling. Histol Hisopathol 2004; 19: 517-525.
50. Collins AR, Schnee J, Wang W, Kim S, Fishbein MC, Bruemmer D, et al. Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. J Am Coll Cardiol 2004; 43: 1698-1705.
51. Lenga Y, Koh A, Perera AS, McCulloch CA, Sodek J, Zohar R. Osteopontin expression is required for myofibroblast differentiation. Circ Res 2008; 102: 319-327.
52. Chablais F, Jazwinska A. The regenerative capacity of the zebrafish heart is dependent on TGFbeta signaling. Development 2012; 139: 1921-1930.
53. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: One function, multiple origins. Am J Pathol 2007; 170: 1807-1816.
54. Ballard VL, Sharma A, Duignan I, Holm JM, Chin A, Choi R, et al. Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularization. FASEB J 2006; 20: 717-719.
55. Aoki T, Fukumoto Y, Sugimura K, Oikawa M, Satoh K, Nakano M, et al. Prognostic impact of myocardial interstitial fibrosis in nonischemic heart failure: Comparison between preserved and reduced ejection fraction heart failure. Circ J 2011; 75: 2605-2613.
56. Kii I, Nishiyama T, Li M, Matsumoto K, Saito M, Amizuka N, et al. Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J Biol Chem 2010; 285: 2028-2039.
57. Manabe I. Chronic inflammation links cardiovascular, metabolic and renal diseases. Circ J 2011; 75: 2739-2748.
58. Lange K, Kammerer M, Hegi ME, Grotegut S, Dittmann A, Huang W, et al. Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization. Cancer Res 2007; 67: 6163-6173.
59. Nagaharu K, Zhang X, Yoshida T, Katoh D, Hanamura N, Kozuka Y, et al. Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. Am J Pathol 2011; 178: 754-763.
60. Sato A, Hiroe M, Akiyama D, Hikita H, Nozato T, Hoshi T, et al. Prognostic value of serum tenascin-C levels on long-term outcome after acute myocardial infarction. J Card Fail 2012; 18: 480-486.
61. Terasaki F, Okamoto H, Onishi K, Sato A, Shimomura H, Tsukada B, et al. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J 2007; 71: 327-330.
62. Fujimoto N, Onishi K, Sato A, Terasaki F, Tsukada B, Nozato T, et al. Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure. J Card Fail 2009; 15: 898-905.
63. Franz M, Berndt A, Altendorf-Hofmann A, Fiedler N, Richter P, Schumm J, et al. Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy. Eur J Heart Fail 2009; 11: 1057-1062.
64. Hessel M, Steendijk P, den Adel B, Schutte C, van der Laarse A. Pressure overload-induced right ventricular failure is associated with re-expression of myocardial tenascin-C and elevated plasma tenascin-C levels. Cell Physiol Biochem 2009; 24: 201-210.
65. Milting H, Ellinghaus P, Seewald M, Cakar H, Bohms B, Kassner A, et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008; 27: 589-596.
66. Kitaoka H, Kubo T, Baba Y, Yamasaki N, Matsumura Y, Furuno T, et al. Serum tenascin-C levels as a prognostic biomarker of heart failure events in patients with hypertrophic cardiomyopathy. J Cardiol 2012; 59: 209-214.
67. Niebroj-Dobosz I, Madej-Pilarczyk A, Marchel M, Sokolowska B, Hausmanowa-Petrusewicz I. Circulating tenascin-C levels in patients with dilated cardiomyopathy in the course of Emery-Dreifuss muscular dystrophy. Clin Chim Acta 2011; 412: 1533-1538.
68. Liabeuf S, Barreto DV, Kretschmer A, Barreto FC, Renard C, Andrejak M, et al. High circulating levels of large splice variants of tenascin-C is associated with mortality and cardiovascular disease in chronic kidney disease patients. Atherosclerosis 2011; 215: 116-124.
69. Kobayashi N, Odaka K, Uehara T, Imanaka-Yoshida K, Kato Y, Oyama H, et al. Toward in vivo imaging of heart disease using a radiolabeled single-chain Fv fragment targeting tenascin-C. Anal Chem 2011; 83: 9123-9130.
70. Golledge J, Clancy P, Maguire J, Lincz L, Koblar S. The role of tenascin C in cardiovascular disease. Cardiovasc Res 2011; 92: 19-28.
71. Hedin U, Holm J, Hansson GK. Induction of tenascin in rat arterial injury: Relationship to altered smooth muscle cell phenotype. Am J Pathol 1991; 139: 649-656.
72. Wallner K, Shah PK, Sharifi BG. Balloon catheterization induces arterial expression of new tenascin-C isoform. Atherosclerosis 2002; 161: 75-83.
73. Imanaka-Yoshida K, Matsuura R, Isaka N, Nakano T, Sakakura T, Yoshida T. Serial extracellular matrix changes in neointimal lesions of human coronary artery after percutaneous transluminal coronary angioplasty: Clinical significance of early tenascin-C expression. Virchows Arch 2001; 439: 185-190.
74. Wang M, Ihida-Stansbury K, Kothapalli D, Tamby MC, Yu Z, Chen L, et al. Microsomal prostaglandin E2 synthase-1 modulates the response to vascular injury. Circulation 2011; 123: 631-639.
75. Fujinaga K, Onoda K, Yamamoto K, Imanaka-Yoshida K, Takao M, Shimono T, et al. Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts. J Thorac Cardiovasc Surg 2004; 128: 357-363.
76. Yamamoto K, Onoda K, Sawada Y, Fujinaga K, Imanaka-Yoshida K, Yoshida T, et al. Locally applied cilostazol suppresses neointimal hyperplasia and medial thickening in a vein graft model. Ann Thorac Cardiovasc Surg 2007; 13: 322-330.
77. Jin L, Hastings NE, Blackman BR, Somlyo AV. Mechanical properties of the extracellular matrix alter expression of smooth muscle protein LPP and its partner palladin; relationship to early atherosclerosis and vascular injury. J Muscle Res Cell Motil 2009; 30: 41-55.
78. Wallner K, Sharifi BG, Shah PK, Noguchi S, DeLeon H, Wilcox JN. Adventitial remodeling after angioplasty is associated with expression of tenascin mRNA by adventitial myofibroblasts. J Am Coll Cardiol 2001; 37: 655-661.
79. Iso Y, Suzuki H, Sato T, Shoji M, Shibata M, Shimizu N, et al. The mechanism of in-stent restenosis in radius stent: An experimental porcine study. Circ J 2005; 69: 481-487.
80. Wallner K, Li C, Shah PK, Fishbein MC, Forrester JS, Kaul S, et al. Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. Circulation 1999; 99: 1284-1289.
81. Kenji K, Hironori U, Hideya Y, Michinori I, Yasuhiko H, Nobuoki K. Tenascin-C is associated with coronary plaque instability in patients with acute coronary syndromes. Circ J 2004; 68: 198-203.
82. Jones PL, Rabinovitch M. Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation. Circ Res 1996; 79: 1131-1142.
83. Jones PL, Cowan KN, Rabinovitch M. Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am J Pathol 1997; 150: 1349-1360.
84. Ihida-Stansbury K, McKean DM, Lane KB, Loyd JE, Wheeler LA, Morrell NW, et al. Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2006; 291: L694-L702.
85. Satta J, Soini Y, Pollanen R, Paakko P, Juvonen T. Tenascin expression is associated with a chronic inflammatory process in abdominal aortic aneurysms. J Vasc Surg 1997; 26: 670-675.
86. Kimura T, Yoshimura K, Aoki H, Imanaka-Yoshida K, Yoshida T, Ikeda Y, et al. Tenascin-C is expressed in abdominal aortic aneurysm tissue with an active degradation process. Pathol Int 2011; 61: 559-564.
87. Didangelos A, Yin X, Mandal K, Saje A, Smith A, Xu Q, et al. Extracellular matrix composition and remodeling in human abdominal aortic aneurysms: A proteomics approach. Mol Cell Proteomics 2011; 10: M111.008128.
88. Shiba M, Suzuki H, Fujimoto M, Shimojo N, Imanaka-Yoshida K, Yoshida T, et al. Imatinib mesylate prevents cerebral vasospasm after subarachnoid hemorrhage via inhibiting tenascin-C expression in rats. Neurobiol Dis 2012; 46: 172-179.
89. Suzuki H, Kanamaru K, Shiba M, Fujimoto M, Imanaka-Yoshida K, Yoshida T, et al. Cerebrospinal fluid tenascin-C in cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg Anesthesiol 2011; 23: 310-317.
90. Suzuki H, Kanamaru K, Suzuki Y, Aimi Y, Matsubara N, Araki T, et al. Tenascin-C is induced in cerebral vasospasm after subarachnoid hemorrhage in rats and humans: A pilot study. Neurol Res 2010; 32: 179-184.
91. Suzuki H, Kinoshita N, Imanaka-Yoshida K, Yoshida T, Taki W. Cerebrospinal fluid tenascin-C increases preceding the development of chronic shunt-dependent hydrocephalus after subarachnoid hemorrhage. Stroke 2008; 39: 1610-1612.
92. Cowan KN, Jones PL, Rabinovitch M. Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. Circ Res 1999; 84: 1223-1233.
93. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S20-S31.
94. Minear MA, Crosslin DR, Sutton BS, Connelly JJ, Nelson SC, Gadson-Watson S, et al. Polymorphic variants in tenascin-C (TNC) are associated with atherosclerosis and coronary artery disease. Hum Genet 2011; 129: 641-654.
95. Hao H, Ishibashi-Ueda H, Tsujimoto M, Ueda Y, Shite J, Gabbiani G, et al. Drug-eluting stent: Importance of clinico-pathological correlations. Circ J 2011; 75: 1548-1558.
96. von Lukowicz T, Silacci M, Wyss MT, Trachsel E, Lohmann C, Buck A, et al. Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo. J Nucl Med 2007; 48: 582-587.
97. Toma N, Imanaka-Yoshida K, Takeuchi T, Matsushima S, Iwata H, Yoshida T, et al. Tenascin-C-coated platinum coils for acceleration of organization of cavities and reduction of lumen size in a rat aneurysm model. J Neurosurg 2005; 103: 681-686.